nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—dilated cardiomyopathy	0.659	1	CbGaD
Thalidomide—CYP2C9—cardial valve—dilated cardiomyopathy	0.013	0.332	CbGeAlD
Thalidomide—Pomalidomide—TNF—dilated cardiomyopathy	0.0041	1	CrCbGaD
Thalidomide—NFKB1—myocardium—dilated cardiomyopathy	0.00393	0.101	CbGeAlD
Thalidomide—CRBN—cardiac ventricle—dilated cardiomyopathy	0.0035	0.0896	CbGeAlD
Thalidomide—CRBN—myocardium—dilated cardiomyopathy	0.00329	0.0843	CbGeAlD
Thalidomide—NFKB1—heart—dilated cardiomyopathy	0.00274	0.0702	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—dilated cardiomyopathy	0.00235	0.06	CbGeAlD
Thalidomide—CRBN—heart—dilated cardiomyopathy	0.0023	0.0588	CbGeAlD
Thalidomide—CRBN—cardiac atrium—dilated cardiomyopathy	0.00197	0.0503	CbGeAlD
Thalidomide—CYP1A1—cardiac ventricle—dilated cardiomyopathy	0.00114	0.0291	CbGeAlD
Thalidomide—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.000954	0.00551	CcSEcCtD
Thalidomide—Lightheadedness—Furosemide—dilated cardiomyopathy	0.000943	0.00545	CcSEcCtD
Thalidomide—PTGS1—myocardium—dilated cardiomyopathy	0.000939	0.024	CbGeAlD
Thalidomide—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00092	0.00531	CcSEcCtD
Thalidomide—Mental disability—Furosemide—dilated cardiomyopathy	0.000915	0.00528	CcSEcCtD
Thalidomide—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0009	0.0052	CcSEcCtD
Thalidomide—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.0009	0.0052	CcSEcCtD
Thalidomide—Accidental injury—Lisinopril—dilated cardiomyopathy	0.000894	0.00516	CcSEcCtD
Thalidomide—Protein urine present—Lisinopril—dilated cardiomyopathy	0.000888	0.00513	CcSEcCtD
Thalidomide—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.000884	0.00511	CcSEcCtD
Thalidomide—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00088	0.00508	CcSEcCtD
Thalidomide—Viral infection—Lisinopril—dilated cardiomyopathy	0.000876	0.00506	CcSEcCtD
Thalidomide—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000872	0.00503	CcSEcCtD
Thalidomide—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00087	0.00502	CcSEcCtD
Thalidomide—Alopecia—Spironolactone—dilated cardiomyopathy	0.00086	0.00497	CcSEcCtD
Thalidomide—Oliguria—Lisinopril—dilated cardiomyopathy	0.000858	0.00496	CcSEcCtD
Thalidomide—Deafness—Furosemide—dilated cardiomyopathy	0.000855	0.00494	CcSEcCtD
Thalidomide—Vascular purpura—Furosemide—dilated cardiomyopathy	0.000855	0.00494	CcSEcCtD
Thalidomide—Drug interaction—Lisinopril—dilated cardiomyopathy	0.000853	0.00492	CcSEcCtD
Thalidomide—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.000842	0.00486	CcSEcCtD
Thalidomide—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.000831	0.0048	CcSEcCtD
Thalidomide—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000814	0.0047	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.000811	0.00468	CcSEcCtD
Thalidomide—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000801	0.00462	CcSEcCtD
Thalidomide—Neck pain—Lisinopril—dilated cardiomyopathy	0.000801	0.00462	CcSEcCtD
Thalidomide—Purpura—Furosemide—dilated cardiomyopathy	0.000794	0.00459	CcSEcCtD
Thalidomide—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.000791	0.00457	CcSEcCtD
Thalidomide—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.000786	0.00454	CcSEcCtD
Thalidomide—Lethargy—Furosemide—dilated cardiomyopathy	0.000781	0.00451	CcSEcCtD
Thalidomide—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000777	0.00449	CcSEcCtD
Thalidomide—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000768	0.00444	CcSEcCtD
Thalidomide—Malaise—Spironolactone—dilated cardiomyopathy	0.000764	0.00441	CcSEcCtD
Thalidomide—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000758	0.00438	CcSEcCtD
Thalidomide—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.000747	0.00431	CcSEcCtD
Thalidomide—CYP1A1—heart—dilated cardiomyopathy	0.000746	0.0191	CbGeAlD
Thalidomide—Neuropathy—Lisinopril—dilated cardiomyopathy	0.000743	0.00429	CcSEcCtD
Thalidomide—CYP2C9—heart—dilated cardiomyopathy	0.000718	0.0184	CbGeAlD
Thalidomide—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000717	0.00414	CcSEcCtD
Thalidomide—Discomfort—Spironolactone—dilated cardiomyopathy	0.000713	0.00411	CcSEcCtD
Thalidomide—Dehydration—Furosemide—dilated cardiomyopathy	0.000712	0.00411	CcSEcCtD
Thalidomide—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000708	0.00409	CcSEcCtD
Thalidomide—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000704	0.00407	CcSEcCtD
Thalidomide—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000699	0.00404	CcSEcCtD
Thalidomide—Confusional state—Spironolactone—dilated cardiomyopathy	0.000697	0.00403	CcSEcCtD
Thalidomide—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000696	0.00402	CcSEcCtD
Thalidomide—Hypertonia—Lisinopril—dilated cardiomyopathy	0.000693	0.004	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000689	0.00398	CcSEcCtD
Thalidomide—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000689	0.00398	CcSEcCtD
Thalidomide—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000677	0.00391	CcSEcCtD
Thalidomide—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000675	0.0039	CcSEcCtD
Thalidomide—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000666	0.00385	CcSEcCtD
Thalidomide—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00066	0.00381	CcSEcCtD
Thalidomide—PTGS1—heart—dilated cardiomyopathy	0.000655	0.0168	CbGeAlD
Thalidomide—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000655	0.00378	CcSEcCtD
Thalidomide—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000654	0.00378	CcSEcCtD
Thalidomide—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000648	0.00374	CcSEcCtD
Thalidomide—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000648	0.00374	CcSEcCtD
Thalidomide—Eczema—Lisinopril—dilated cardiomyopathy	0.000639	0.00369	CcSEcCtD
Thalidomide—CYP1A1—cardiac atrium—dilated cardiomyopathy	0.000638	0.0163	CbGeAlD
Thalidomide—PTGS2—heart—dilated cardiomyopathy	0.000626	0.016	CbGeAlD
Thalidomide—Injury—Lisinopril—dilated cardiomyopathy	0.000625	0.00361	CcSEcCtD
Thalidomide—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.000622	0.00359	CcSEcCtD
Thalidomide—Libido decreased—Lisinopril—dilated cardiomyopathy	0.000619	0.00358	CcSEcCtD
Thalidomide—Somnolence—Spironolactone—dilated cardiomyopathy	0.000615	0.00355	CcSEcCtD
Thalidomide—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000611	0.00353	CcSEcCtD
Thalidomide—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000606	0.0035	CcSEcCtD
Thalidomide—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000604	0.00349	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000597	0.00345	CcSEcCtD
Thalidomide—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000597	0.00345	CcSEcCtD
Thalidomide—Arthritis—Lisinopril—dilated cardiomyopathy	0.000591	0.00341	CcSEcCtD
Thalidomide—Drowsiness—Furosemide—dilated cardiomyopathy	0.00059	0.00341	CcSEcCtD
Thalidomide—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000588	0.0034	CcSEcCtD
Thalidomide—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000586	0.00338	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000585	0.00338	CcSEcCtD
Thalidomide—Renal failure—Furosemide—dilated cardiomyopathy	0.00058	0.00335	CcSEcCtD
Thalidomide—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000576	0.00333	CcSEcCtD
Thalidomide—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.000574	0.00332	CcSEcCtD
Thalidomide—Diplopia—Lisinopril—dilated cardiomyopathy	0.000574	0.00332	CcSEcCtD
Thalidomide—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000574	0.00332	CcSEcCtD
Thalidomide—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00057	0.00329	CcSEcCtD
Thalidomide—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00057	0.00329	CcSEcCtD
Thalidomide—Sweating—Furosemide—dilated cardiomyopathy	0.000565	0.00326	CcSEcCtD
Thalidomide—PTGS1—cardiac atrium—dilated cardiomyopathy	0.00056	0.0143	CbGeAlD
Thalidomide—Face oedema—Lisinopril—dilated cardiomyopathy	0.000554	0.0032	CcSEcCtD
Thalidomide—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00055	0.00318	CcSEcCtD
Thalidomide—Urticaria—Spironolactone—dilated cardiomyopathy	0.000549	0.00317	CcSEcCtD
Thalidomide—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000547	0.00316	CcSEcCtD
Thalidomide—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000546	0.00315	CcSEcCtD
Thalidomide—Ataxia—Lisinopril—dilated cardiomyopathy	0.00054	0.00312	CcSEcCtD
Thalidomide—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000538	0.00311	CcSEcCtD
Thalidomide—Dehydration—Lisinopril—dilated cardiomyopathy	0.000534	0.00308	CcSEcCtD
Thalidomide—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000524	0.00303	CcSEcCtD
Thalidomide—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000523	0.00302	CcSEcCtD
Thalidomide—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000519	0.003	CcSEcCtD
Thalidomide—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000519	0.003	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000517	0.00299	CcSEcCtD
Thalidomide—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000517	0.00299	CcSEcCtD
Thalidomide—Visual impairment—Furosemide—dilated cardiomyopathy	0.00051	0.00295	CcSEcCtD
Thalidomide—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000509	0.00294	CcSEcCtD
Thalidomide—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000501	0.00289	CcSEcCtD
Thalidomide—Influenza—Lisinopril—dilated cardiomyopathy	0.000496	0.00287	CcSEcCtD
Thalidomide—Eye disorder—Furosemide—dilated cardiomyopathy	0.000495	0.00286	CcSEcCtD
Thalidomide—Tinnitus—Furosemide—dilated cardiomyopathy	0.000494	0.00285	CcSEcCtD
Thalidomide—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000491	0.00284	CcSEcCtD
Thalidomide—Pruritus—Spironolactone—dilated cardiomyopathy	0.000489	0.00282	CcSEcCtD
Thalidomide—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000488	0.00282	CcSEcCtD
Thalidomide—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000487	0.00281	CcSEcCtD
Thalidomide—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000483	0.00279	CcSEcCtD
Thalidomide—Angiopathy—Furosemide—dilated cardiomyopathy	0.00048	0.00277	CcSEcCtD
Thalidomide—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000478	0.00276	CcSEcCtD
Thalidomide—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000477	0.00276	CcSEcCtD
Thalidomide—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000473	0.00273	CcSEcCtD
Thalidomide—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000473	0.00273	CcSEcCtD
Thalidomide—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000471	0.00272	CcSEcCtD
Thalidomide—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000464	0.00268	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000461	0.00266	CcSEcCtD
Thalidomide—Malnutrition—Furosemide—dilated cardiomyopathy	0.000461	0.00266	CcSEcCtD
Thalidomide—Dizziness—Spironolactone—dilated cardiomyopathy	0.000457	0.00264	CcSEcCtD
Thalidomide—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000457	0.00264	CcSEcCtD
Thalidomide—Flatulence—Furosemide—dilated cardiomyopathy	0.000454	0.00262	CcSEcCtD
Thalidomide—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000453	0.00262	CcSEcCtD
Thalidomide—Weight increased—Lisinopril—dilated cardiomyopathy	0.000452	0.00261	CcSEcCtD
Thalidomide—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000451	0.00261	CcSEcCtD
Thalidomide—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000449	0.00259	CcSEcCtD
Thalidomide—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000448	0.00259	CcSEcCtD
Thalidomide—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000445	0.00257	CcSEcCtD
Thalidomide—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000443	0.00256	CcSEcCtD
Thalidomide—Depression—Lisinopril—dilated cardiomyopathy	0.000441	0.00255	CcSEcCtD
Thalidomide—Vomiting—Spironolactone—dilated cardiomyopathy	0.00044	0.00254	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000439	0.00253	CcSEcCtD
Thalidomide—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000436	0.00252	CcSEcCtD
Thalidomide—Rash—Spironolactone—dilated cardiomyopathy	0.000436	0.00252	CcSEcCtD
Thalidomide—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000435	0.00251	CcSEcCtD
Thalidomide—Renal failure—Lisinopril—dilated cardiomyopathy	0.000435	0.00251	CcSEcCtD
Thalidomide—Vision blurred—Furosemide—dilated cardiomyopathy	0.000434	0.00251	CcSEcCtD
Thalidomide—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000434	0.0025	CcSEcCtD
Thalidomide—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000434	0.0025	CcSEcCtD
Thalidomide—Headache—Spironolactone—dilated cardiomyopathy	0.000433	0.0025	CcSEcCtD
Thalidomide—Anaemia—Furosemide—dilated cardiomyopathy	0.000426	0.00246	CcSEcCtD
Thalidomide—Sweating—Lisinopril—dilated cardiomyopathy	0.000424	0.00245	CcSEcCtD
Thalidomide—Agitation—Furosemide—dilated cardiomyopathy	0.000424	0.00245	CcSEcCtD
Thalidomide—Haematuria—Lisinopril—dilated cardiomyopathy	0.000422	0.00244	CcSEcCtD
Thalidomide—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000417	0.00241	CcSEcCtD
Thalidomide—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000415	0.0024	CcSEcCtD
Thalidomide—Vertigo—Furosemide—dilated cardiomyopathy	0.000414	0.00239	CcSEcCtD
Thalidomide—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000413	0.00238	CcSEcCtD
Thalidomide—Leukopenia—Furosemide—dilated cardiomyopathy	0.000413	0.00238	CcSEcCtD
Thalidomide—Nausea—Spironolactone—dilated cardiomyopathy	0.000411	0.00237	CcSEcCtD
Thalidomide—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000404	0.00234	CcSEcCtD
Thalidomide—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000398	0.0023	CcSEcCtD
Thalidomide—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000397	0.00229	CcSEcCtD
Thalidomide—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000394	0.00228	CcSEcCtD
Thalidomide—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000392	0.00227	CcSEcCtD
Thalidomide—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000391	0.00226	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00039	0.00225	CcSEcCtD
Thalidomide—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000389	0.00225	CcSEcCtD
Thalidomide—Dry mouth—Furosemide—dilated cardiomyopathy	0.000384	0.00222	CcSEcCtD
Thalidomide—Confusional state—Furosemide—dilated cardiomyopathy	0.000379	0.00219	CcSEcCtD
Thalidomide—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000376	0.00217	CcSEcCtD
Thalidomide—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00037	0.00214	CcSEcCtD
Thalidomide—Shock—Furosemide—dilated cardiomyopathy	0.00037	0.00214	CcSEcCtD
Thalidomide—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000369	0.00213	CcSEcCtD
Thalidomide—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000368	0.00213	CcSEcCtD
Thalidomide—Skin disorder—Furosemide—dilated cardiomyopathy	0.000365	0.00211	CcSEcCtD
Thalidomide—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000364	0.0021	CcSEcCtD
Thalidomide—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00036	0.00208	CcSEcCtD
Thalidomide—Anorexia—Furosemide—dilated cardiomyopathy	0.000359	0.00207	CcSEcCtD
Thalidomide—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000358	0.00207	CcSEcCtD
Thalidomide—Chills—Lisinopril—dilated cardiomyopathy	0.000356	0.00206	CcSEcCtD
Thalidomide—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000355	0.00205	CcSEcCtD
Thalidomide—Hypotension—Furosemide—dilated cardiomyopathy	0.000351	0.00203	CcSEcCtD
Thalidomide—Alopecia—Lisinopril—dilated cardiomyopathy	0.000351	0.00203	CcSEcCtD
Thalidomide—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000348	0.00201	CcSEcCtD
Thalidomide—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000346	0.002	CcSEcCtD
Thalidomide—Flatulence—Lisinopril—dilated cardiomyopathy	0.000341	0.00197	CcSEcCtD
Thalidomide—Tension—Lisinopril—dilated cardiomyopathy	0.000339	0.00196	CcSEcCtD
Thalidomide—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000339	0.00196	CcSEcCtD
Thalidomide—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000338	0.00195	CcSEcCtD
Thalidomide—Nervousness—Lisinopril—dilated cardiomyopathy	0.000336	0.00194	CcSEcCtD
Thalidomide—Back pain—Lisinopril—dilated cardiomyopathy	0.000334	0.00193	CcSEcCtD
Thalidomide—Somnolence—Furosemide—dilated cardiomyopathy	0.000334	0.00193	CcSEcCtD
Thalidomide—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000332	0.00192	CcSEcCtD
Thalidomide—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000327	0.00189	CcSEcCtD
Thalidomide—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000326	0.00188	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000325	0.00188	CcSEcCtD
Thalidomide—Fatigue—Furosemide—dilated cardiomyopathy	0.000324	0.00187	CcSEcCtD
Thalidomide—Tremor—Lisinopril—dilated cardiomyopathy	0.000324	0.00187	CcSEcCtD
Thalidomide—Constipation—Furosemide—dilated cardiomyopathy	0.000322	0.00186	CcSEcCtD
Thalidomide—Pain—Furosemide—dilated cardiomyopathy	0.000322	0.00186	CcSEcCtD
Thalidomide—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000321	0.00185	CcSEcCtD
Thalidomide—Anaemia—Lisinopril—dilated cardiomyopathy	0.00032	0.00185	CcSEcCtD
Thalidomide—Angioedema—Lisinopril—dilated cardiomyopathy	0.000316	0.00182	CcSEcCtD
Thalidomide—Malaise—Lisinopril—dilated cardiomyopathy	0.000312	0.0018	CcSEcCtD
Thalidomide—Vertigo—Lisinopril—dilated cardiomyopathy	0.000311	0.00179	CcSEcCtD
Thalidomide—Syncope—Lisinopril—dilated cardiomyopathy	0.00031	0.00179	CcSEcCtD
Thalidomide—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00031	0.00179	CcSEcCtD
Thalidomide—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00031	0.00179	CcSEcCtD
Thalidomide—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000308	0.00178	CcSEcCtD
Thalidomide—Palpitations—Lisinopril—dilated cardiomyopathy	0.000306	0.00176	CcSEcCtD
Thalidomide—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000304	0.00176	CcSEcCtD
Thalidomide—Cough—Lisinopril—dilated cardiomyopathy	0.000302	0.00174	CcSEcCtD
Thalidomide—Urticaria—Furosemide—dilated cardiomyopathy	0.000299	0.00173	CcSEcCtD
Thalidomide—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000297	0.00172	CcSEcCtD
Thalidomide—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000297	0.00172	CcSEcCtD
Thalidomide—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000294	0.0017	CcSEcCtD
Thalidomide—Chest pain—Lisinopril—dilated cardiomyopathy	0.000294	0.0017	CcSEcCtD
Thalidomide—Myalgia—Lisinopril—dilated cardiomyopathy	0.000294	0.0017	CcSEcCtD
Thalidomide—Anxiety—Lisinopril—dilated cardiomyopathy	0.000293	0.00169	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000292	0.00169	CcSEcCtD
Thalidomide—Discomfort—Lisinopril—dilated cardiomyopathy	0.000291	0.00168	CcSEcCtD
Thalidomide—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000288	0.00166	CcSEcCtD
Thalidomide—Confusional state—Lisinopril—dilated cardiomyopathy	0.000285	0.00164	CcSEcCtD
Thalidomide—Oedema—Lisinopril—dilated cardiomyopathy	0.000282	0.00163	CcSEcCtD
Thalidomide—Infection—Lisinopril—dilated cardiomyopathy	0.00028	0.00162	CcSEcCtD
Thalidomide—Shock—Lisinopril—dilated cardiomyopathy	0.000278	0.0016	CcSEcCtD
Thalidomide—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000277	0.0016	CcSEcCtD
Thalidomide—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000276	0.0016	CcSEcCtD
Thalidomide—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000275	0.00159	CcSEcCtD
Thalidomide—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000274	0.00158	CcSEcCtD
Thalidomide—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000273	0.00158	CcSEcCtD
Thalidomide—Asthenia—Furosemide—dilated cardiomyopathy	0.00027	0.00156	CcSEcCtD
Thalidomide—Anorexia—Lisinopril—dilated cardiomyopathy	0.000269	0.00155	CcSEcCtD
Thalidomide—Pruritus—Furosemide—dilated cardiomyopathy	0.000266	0.00154	CcSEcCtD
Thalidomide—Hypotension—Lisinopril—dilated cardiomyopathy	0.000264	0.00152	CcSEcCtD
Thalidomide—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000257	0.00149	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000257	0.00148	CcSEcCtD
Thalidomide—Insomnia—Lisinopril—dilated cardiomyopathy	0.000255	0.00147	CcSEcCtD
Thalidomide—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000253	0.00146	CcSEcCtD
Thalidomide—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000252	0.00145	CcSEcCtD
Thalidomide—Somnolence—Lisinopril—dilated cardiomyopathy	0.000251	0.00145	CcSEcCtD
Thalidomide—Dizziness—Furosemide—dilated cardiomyopathy	0.000249	0.00144	CcSEcCtD
Thalidomide—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000248	0.00143	CcSEcCtD
Thalidomide—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000245	0.00142	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000244	0.00141	CcSEcCtD
Thalidomide—Fatigue—Lisinopril—dilated cardiomyopathy	0.000243	0.00141	CcSEcCtD
Thalidomide—Pain—Lisinopril—dilated cardiomyopathy	0.000241	0.00139	CcSEcCtD
Thalidomide—Constipation—Lisinopril—dilated cardiomyopathy	0.000241	0.00139	CcSEcCtD
Thalidomide—Vomiting—Furosemide—dilated cardiomyopathy	0.000239	0.00138	CcSEcCtD
Thalidomide—Rash—Furosemide—dilated cardiomyopathy	0.000237	0.00137	CcSEcCtD
Thalidomide—Dermatitis—Furosemide—dilated cardiomyopathy	0.000237	0.00137	CcSEcCtD
Thalidomide—Headache—Furosemide—dilated cardiomyopathy	0.000236	0.00136	CcSEcCtD
Thalidomide—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000233	0.00134	CcSEcCtD
Thalidomide—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000231	0.00133	CcSEcCtD
Thalidomide—Urticaria—Lisinopril—dilated cardiomyopathy	0.000224	0.00129	CcSEcCtD
Thalidomide—Nausea—Furosemide—dilated cardiomyopathy	0.000223	0.00129	CcSEcCtD
Thalidomide—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000223	0.00129	CcSEcCtD
Thalidomide—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000223	0.00129	CcSEcCtD
Thalidomide—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000208	0.0012	CcSEcCtD
Thalidomide—Asthenia—Lisinopril—dilated cardiomyopathy	0.000202	0.00117	CcSEcCtD
Thalidomide—Pruritus—Lisinopril—dilated cardiomyopathy	0.0002	0.00115	CcSEcCtD
Thalidomide—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000193	0.00112	CcSEcCtD
Thalidomide—Dizziness—Lisinopril—dilated cardiomyopathy	0.000187	0.00108	CcSEcCtD
Thalidomide—Vomiting—Lisinopril—dilated cardiomyopathy	0.000179	0.00104	CcSEcCtD
Thalidomide—Rash—Lisinopril—dilated cardiomyopathy	0.000178	0.00103	CcSEcCtD
Thalidomide—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000178	0.00103	CcSEcCtD
Thalidomide—Headache—Lisinopril—dilated cardiomyopathy	0.000177	0.00102	CcSEcCtD
Thalidomide—Nausea—Lisinopril—dilated cardiomyopathy	0.000168	0.000968	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000138	0.0011	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—dilated cardiomyopathy	0.000137	0.0011	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000137	0.0011	CbGpPWpGaD
Thalidomide—NFKB1—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000136	0.00109	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000135	0.00108	CbGpPWpGaD
Thalidomide—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000134	0.00107	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000132	0.00106	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	0.000132	0.00106	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000132	0.00105	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.00013	0.00104	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000128	0.00102	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	0.000127	0.00102	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000127	0.00102	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000126	0.00101	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000126	0.00101	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000125	0.001	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000124	0.000991	CbGpPWpGaD
Thalidomide—FGFR2—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000121	0.000965	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000121	0.000964	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000119	0.00095	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000118	0.000946	CbGpPWpGaD
Thalidomide—FGFR2—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000118	0.000942	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000118	0.000942	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	0.000117	0.000938	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000117	0.000937	CbGpPWpGaD
Thalidomide—FGFR2—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000117	0.000935	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000117	0.000933	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000116	0.000929	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000116	0.000925	CbGpPWpGaD
Thalidomide—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000114	0.000914	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000114	0.000909	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.000113	0.000905	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000113	0.000901	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.000111	0.000886	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000111	0.000884	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.00011	0.000878	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—RAF1—dilated cardiomyopathy	0.00011	0.000877	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.00011	0.000877	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.00011	0.000877	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000109	0.00087	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000109	0.000869	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000108	0.000862	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000107	0.000858	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000105	0.000836	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000104	0.000832	CbGpPWpGaD
Thalidomide—CYP1A1—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.000102	0.000815	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000101	0.000806	CbGpPWpGaD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	9.98e-05	0.000798	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	9.78e-05	0.000782	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	9.74e-05	0.000779	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	9.74e-05	0.000779	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	9.72e-05	0.000777	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—ITGB1—dilated cardiomyopathy	9.54e-05	0.000763	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.48e-05	0.000758	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	9.28e-05	0.000742	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	9.28e-05	0.000742	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	9.18e-05	0.000734	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	9.16e-05	0.000733	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	9.06e-05	0.000725	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	9.02e-05	0.000722	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	9e-05	0.00072	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	8.63e-05	0.00069	CbGpPWpGaD
Thalidomide—FGFR2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	8.63e-05	0.00069	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.62e-05	0.000689	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ANKRD1—dilated cardiomyopathy	8.54e-05	0.000683	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB4—EGFR—dilated cardiomyopathy	8.5e-05	0.00068	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—EGFR—dilated cardiomyopathy	8.36e-05	0.000668	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	8.35e-05	0.000668	CbGpPWpGaD
Thalidomide—NFKB1—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	8.31e-05	0.000664	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	8.29e-05	0.000663	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	8.27e-05	0.000661	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	8.18e-05	0.000654	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CD36—dilated cardiomyopathy	8.14e-05	0.000651	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—EGFR—dilated cardiomyopathy	8.12e-05	0.000649	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	8.1e-05	0.000648	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ITGB1—dilated cardiomyopathy	8.09e-05	0.000647	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—EGFR—dilated cardiomyopathy	8.08e-05	0.000646	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—EGFR—dilated cardiomyopathy	8.04e-05	0.000643	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TAZ—dilated cardiomyopathy	8.03e-05	0.000642	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	8.01e-05	0.000641	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—EGFR—dilated cardiomyopathy	8e-05	0.000639	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	7.93e-05	0.000634	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	7.89e-05	0.000631	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	7.88e-05	0.00063	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—RAF1—dilated cardiomyopathy	7.88e-05	0.00063	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	7.87e-05	0.00063	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	7.84e-05	0.000627	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	7.73e-05	0.000618	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ITGB1—dilated cardiomyopathy	7.68e-05	0.000614	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—RAC1—dilated cardiomyopathy	7.67e-05	0.000613	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	7.63e-05	0.000611	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	7.52e-05	0.000602	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—EGFR—dilated cardiomyopathy	7.52e-05	0.000602	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	7.52e-05	0.000602	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—RAF1—dilated cardiomyopathy	7.47e-05	0.000598	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	7.46e-05	0.000597	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—EGFR—dilated cardiomyopathy	7.46e-05	0.000596	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	7.39e-05	0.000591	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—EGFR—dilated cardiomyopathy	7.36e-05	0.000588	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—EGFR—dilated cardiomyopathy	7.34e-05	0.000587	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—ITGB1—dilated cardiomyopathy	7.27e-05	0.000581	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SDHA—dilated cardiomyopathy	7.26e-05	0.000581	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD36—dilated cardiomyopathy	7.19e-05	0.000575	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	7.11e-05	0.000568	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NPPA—dilated cardiomyopathy	7.1e-05	0.000568	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—EGFR—dilated cardiomyopathy	6.96e-05	0.000557	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD36—dilated cardiomyopathy	6.9e-05	0.000552	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PSEN2—dilated cardiomyopathy	6.87e-05	0.00055	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	6.87e-05	0.00055	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD36—dilated cardiomyopathy	6.82e-05	0.000546	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	6.78e-05	0.000542	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—RAC1—dilated cardiomyopathy	6.78e-05	0.000542	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	6.66e-05	0.000533	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD36—dilated cardiomyopathy	6.55e-05	0.000524	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—RAC1—dilated cardiomyopathy	6.51e-05	0.00052	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—RAC1—dilated cardiomyopathy	6.43e-05	0.000514	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	6.38e-05	0.000511	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	6.38e-05	0.00051	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	6.37e-05	0.00051	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	6.3e-05	0.000504	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	6.22e-05	0.000498	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	6.21e-05	0.000497	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	6.21e-05	0.000497	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CD36—dilated cardiomyopathy	6.2e-05	0.000496	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—RAC1—dilated cardiomyopathy	6.17e-05	0.000494	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ANKRD1—dilated cardiomyopathy	6.02e-05	0.000481	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	6e-05	0.00048	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	5.99e-05	0.000479	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	5.92e-05	0.000473	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	5.92e-05	0.000473	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—RAC1—dilated cardiomyopathy	5.84e-05	0.000467	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	5.77e-05	0.000461	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.68e-05	0.000455	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TAZ—dilated cardiomyopathy	5.66e-05	0.000453	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	5.43e-05	0.000434	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	5.42e-05	0.000433	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—dilated cardiomyopathy	5.4e-05	0.000432	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	5.17e-05	0.000413	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	5.13e-05	0.00041	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—dilated cardiomyopathy	5.12e-05	0.00041	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SDHA—dilated cardiomyopathy	5.12e-05	0.000409	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—RAF1—dilated cardiomyopathy	5.09e-05	0.000407	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.07e-05	0.000406	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	4.93e-05	0.000394	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	4.92e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ITGB1—dilated cardiomyopathy	4.91e-05	0.000393	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.81e-05	0.000385	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ITGB1—dilated cardiomyopathy	4.66e-05	0.000372	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	4.63e-05	0.00037	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.5e-05	0.00036	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.5e-05	0.00036	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—RAF1—dilated cardiomyopathy	4.49e-05	0.000359	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	4.49e-05	0.000359	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.43e-05	0.000354	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.32e-05	0.000345	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.31e-05	0.000345	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.27e-05	0.000342	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.27e-05	0.000342	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—RAF1—dilated cardiomyopathy	4.26e-05	0.000341	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	4.22e-05	0.000338	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	4.19e-05	0.000335	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.19e-05	0.000335	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD36—dilated cardiomyopathy	4.19e-05	0.000335	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—RAF1—dilated cardiomyopathy	4.09e-05	0.000327	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.06e-05	0.000324	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.97e-05	0.000318	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD36—dilated cardiomyopathy	3.97e-05	0.000318	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RAC1—dilated cardiomyopathy	3.95e-05	0.000316	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.89e-05	0.000311	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—RAF1—dilated cardiomyopathy	3.88e-05	0.00031	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.85e-05	0.000308	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3.84e-05	0.000307	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	3.82e-05	0.000305	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RAC1—dilated cardiomyopathy	3.74e-05	0.000299	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.61e-05	0.000289	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NPPA—dilated cardiomyopathy	3.53e-05	0.000282	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.52e-05	0.000281	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.52e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—dilated cardiomyopathy	3.49e-05	0.000279	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.46e-05	0.000277	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RAC1—dilated cardiomyopathy	3.46e-05	0.000276	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.43e-05	0.000274	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PSEN2—dilated cardiomyopathy	3.41e-05	0.000273	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.35e-05	0.000268	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—dilated cardiomyopathy	3.32e-05	0.000266	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.29e-05	0.000263	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.29e-05	0.000263	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	3.26e-05	0.000261	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.12e-05	0.00025	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.12e-05	0.000249	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.08e-05	0.000247	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—dilated cardiomyopathy	3.08e-05	0.000246	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.04e-05	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.96e-05	0.000237	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—dilated cardiomyopathy	2.92e-05	0.000234	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.82e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—dilated cardiomyopathy	2.81e-05	0.000224	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.74e-05	0.000219	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.68e-05	0.000214	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—dilated cardiomyopathy	2.66e-05	0.000213	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—RAF1—dilated cardiomyopathy	2.62e-05	0.000209	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.55e-05	0.000204	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.55e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.49e-05	0.000199	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—RAF1—dilated cardiomyopathy	2.48e-05	0.000199	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AGT—dilated cardiomyopathy	2.44e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.42e-05	0.000194	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.33e-05	0.000186	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AGT—dilated cardiomyopathy	2.31e-05	0.000185	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RAF1—dilated cardiomyopathy	2.29e-05	0.000183	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.27e-05	0.000181	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.24e-05	0.000179	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.04e-05	0.000163	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.99e-05	0.000159	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	1.97e-05	0.000158	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.94e-05	0.000155	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CD36—dilated cardiomyopathy	1.92e-05	0.000154	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—dilated cardiomyopathy	1.79e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.75e-05	0.00014	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AGT—dilated cardiomyopathy	1.73e-05	0.000138	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAC1—dilated cardiomyopathy	1.72e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—dilated cardiomyopathy	1.7e-05	0.000136	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.69e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.61e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—dilated cardiomyopathy	1.57e-05	0.000126	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	1.57e-05	0.000125	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CD36—dilated cardiomyopathy	1.53e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	1.47e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	1.47e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	1.44e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	1.43e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GPX1—dilated cardiomyopathy	1.39e-05	0.000111	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AGT—dilated cardiomyopathy	1.37e-05	0.00011	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CD36—dilated cardiomyopathy	1.35e-05	0.000108	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	1.29e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	1.29e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AGT—dilated cardiomyopathy	1.22e-05	9.75e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.16e-05	9.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAF1—dilated cardiomyopathy	1.14e-05	9.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	1.14e-05	9.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	1.11e-05	8.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.1e-05	8.8e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	1.04e-05	8.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	1.01e-05	8.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	9.98e-06	7.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	9.1e-06	7.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	8.87e-06	7.09e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	8.63e-06	6.9e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—dilated cardiomyopathy	7.81e-06	6.24e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	7.77e-06	6.22e-05	CbGpPWpGaD
